PriceTargets.com logo

Tourmaline Bio - TRML Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $45.65
  • Forecasted Upside: -4.86%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 9 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$47.98 As of 10/28/2025 04:30 PM ET
+0 (0.00%)

This chart shows the closing price for TRML by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tourmaline Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRML and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRML

Analyst Price Target is $45.65
▼ -4.86% Downside Potential
This price target is based on 11 analysts offering 12 month price targets for Tourmaline Bio in the last 3 months. The average price target is $45.65, with a high forecast of $48.00 and a low forecast of $25.00. The average price target represents a -4.86% upside from the last price of $47.98.

This chart shows the closing price for TRML for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 contributing investment analysts is to hold stock in Tourmaline Bio. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 9 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/15/2025BMO Capital MarketsDowngradeOutperform ➝ Market Perform$35.00 ➝ $48.00
9/11/2025Piper SandlerDowngradeOverweight ➝ Neutral$65.00 ➝ $48.00
9/10/2025Truist FinancialDowngradeBuy ➝ Hold$63.00 ➝ $48.00
9/10/2025GuggenheimReiterated RatingBuy ➝ Neutral$55.00 ➝ $48.00
9/10/2025HC WainwrightDowngradeBuy ➝ Neutral$50.00 ➝ $48.00
9/10/2025Chardan CapitalDowngradeBuy ➝ Neutral$70.00 ➝ $48.00
9/9/2025GuggenheimDowngradeBuy ➝ Hold
9/9/2025Jefferies Financial GroupDowngradeBuy ➝ Hold$64.00 ➝ $47.50
9/9/2025Lifesci CapitalDowngradeOutperform ➝ Hold$48.00
9/9/2025WedbushDowngradeOutperform ➝ Neutral$48.00
8/14/2025Chardan CapitalReiterated RatingBuy ➝ Buy$70.00
8/14/2025GuggenheimReiterated RatingBuy ➝ Buy$55.00
5/5/2025Chardan CapitalReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
5/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
4/23/2025Chardan CapitalInitiated CoverageBuy$70.00
3/14/2025WedbushBoost TargetOutperform ➝ Outperform$42.00 ➝ $43.00
3/14/2025HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $50.00
3/6/2025WedbushInitiated CoverageOutperform$42.00
2/24/2025Lifesci CapitalInitiated CoverageOutperform$58.00
12/11/2024GuggenheimReiterated RatingBuy ➝ Buy
12/11/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
12/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
12/6/2024BMO Capital MarketsInitiated CoverageOutperform$50.00
11/11/2024HC WainwrightBoost TargetBuy ➝ Buy$48.00 ➝ $49.00
10/15/2024Cantor FitzgeraldUpgradeStrong-Buy
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $48.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$74.00
3/20/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$41.00 ➝ $72.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00
12/15/2023Jefferies Financial GroupInitiated CoverageBuy$41.00
12/7/2023Leerink PartnrsReiterated RatingOutperform
12/4/2023HC WainwrightReiterated RatingBuy
11/17/2023Truist FinancialInitiated CoverageBuy$43.00
10/31/2023GuggenheimInitiated CoverageBuy$50.00
10/25/2023Piper SandlerInitiated CoverageOverweight$65.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 14 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 14 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 15 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Tourmaline Bio logo
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Read More

Today's Range

Now: $47.98
Low: $47.98
High: $48.00

50 Day Range

MA: $47.95
Low: $47.74
High: $48.16

52 Week Range

Now: $47.98
Low: $11.56
High: $48.27

Volume

783,700 shs

Average Volume

653,270 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Tourmaline Bio?

The following sell-side analysts have issued research reports on Tourmaline Bio in the last twelve months: BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Piper Sandler, Truist Financial Corporation, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for TRML.

What is the current price target for Tourmaline Bio?

0 Wall Street analysts have set twelve-month price targets for Tourmaline Bio in the last year. Their average twelve-month price target is $45.65, suggesting a possible downside of 4.9%. BMO Capital Markets has the highest price target set, predicting TRML will reach $48.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $25.00 for Tourmaline Bio in the next year.
View the latest price targets for TRML.

What is the current consensus analyst rating for Tourmaline Bio?

Tourmaline Bio currently has 1 sell rating, 9 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRML, but not buy more shares or sell existing shares.
View the latest ratings for TRML.

What other companies compete with Tourmaline Bio?

Other companies that are similar to Tourmaline Bio include Apogee Therapeutics, Praxis Precision Medicines, Kymera Therapeutics, Belite Bio and NewAmsterdam Pharma. Learn More about companies similar to Tourmaline Bio.

How do I contact Tourmaline Bio's investor relations team?

Tourmaline Bio's physical mailing address is 93 WORCESTER STREET, WELLESLEY MA, 02481. The company's listed phone number is 502-398-9250 and its investor relations email address is [email protected]. The official website for Tourmaline Bio is talaristx.com. Learn More about contacing Tourmaline Bio investor relations.